Cargando…
Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi
BACKGROUND: The most common apicomplexan parasites causing bovine babesiosis are Babesia bovis and B. bigemina, while B. caballi and Theileria equi are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712603/ https://www.ncbi.nlm.nih.gov/pubmed/33272316 http://dx.doi.org/10.1186/s13071-020-04487-3 |
_version_ | 1783618408398454784 |
---|---|
author | Silva, Marta G. Bastos, Reginaldo G. Stone Doggett, J. Riscoe, Michael K. Pou, Sovitj Winter, Rolf Dodean, Rozalia A. Nilsen, Aaron Suarez, Carlos E. |
author_facet | Silva, Marta G. Bastos, Reginaldo G. Stone Doggett, J. Riscoe, Michael K. Pou, Sovitj Winter, Rolf Dodean, Rozalia A. Nilsen, Aaron Suarez, Carlos E. |
author_sort | Silva, Marta G. |
collection | PubMed |
description | BACKGROUND: The most common apicomplexan parasites causing bovine babesiosis are Babesia bovis and B. bigemina, while B. caballi and Theileria equi are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such as imidocarb diproprionate, but drug-resistant parasites are emerging, and alternative effective and safer drugs are needed. The endochin-like quinolones (ELQ)-300 and ELQ-316 have been proven to be safe and efficacious against related apicomplexans, such as Plasmodium spp., with ELQ-316 also being effective against Babesia microti, without showing toxicity in mammals. METHODS: The inhibitory effects of ELQ-300 and ELQ-316 were assessed on the growth of cultured B. bovis, B. bigemina, B. caballi and T. equi. The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of the ELQ compounds on the viability of horse and bovine peripheral blood mononuclear cells (PBMC) was assessed by monitoring cell metabolic activity using a colorimetric assay. RESULTS: We calculated the half maximal inhibitory concentration (IC(50)) at 72 h, which ranged from 0.04 to 0.37 nM for ELQ-300, and from 0.002 to 0.1 nM for ELQ-316 among all cultured parasites tested at 72 h. None of the parasites tested were able to replicate in cultures in the presence of ELQ-300 and ELQ-316 at the maximal inhibitory concentration (IC(100)), which ranged from 1.3 to 5.7 nM for ELQ-300 and from 1.0 to 6.0 nM for ELQ-316 at 72 h. Neither ELQ-300 nor ELQ-316 altered the viability of equine and bovine PBMC at their IC(100) in in vitro testing. CONCLUSIONS: The compounds ELQ-300 and ELQ-316 showed significant inhibitory activity on the main parasites responsible for bovine babesiosis and equine piroplasmosis at doses that are tolerable to host cells. These ELQ drugs may be viable candidates for developing alternative protocols for the treatment of bovine babesiosis and equine piroplasmosis. [Image: see text] |
format | Online Article Text |
id | pubmed-7712603 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77126032020-12-03 Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi Silva, Marta G. Bastos, Reginaldo G. Stone Doggett, J. Riscoe, Michael K. Pou, Sovitj Winter, Rolf Dodean, Rozalia A. Nilsen, Aaron Suarez, Carlos E. Parasit Vectors Research BACKGROUND: The most common apicomplexan parasites causing bovine babesiosis are Babesia bovis and B. bigemina, while B. caballi and Theileria equi are responsible for equine piroplasmosis. Treatment and control of these diseases are usually achieved using potentially toxic chemotherapeutics, such as imidocarb diproprionate, but drug-resistant parasites are emerging, and alternative effective and safer drugs are needed. The endochin-like quinolones (ELQ)-300 and ELQ-316 have been proven to be safe and efficacious against related apicomplexans, such as Plasmodium spp., with ELQ-316 also being effective against Babesia microti, without showing toxicity in mammals. METHODS: The inhibitory effects of ELQ-300 and ELQ-316 were assessed on the growth of cultured B. bovis, B. bigemina, B. caballi and T. equi. The percentage of parasitized erythrocytes was measured by flow cytometry, and the effect of the ELQ compounds on the viability of horse and bovine peripheral blood mononuclear cells (PBMC) was assessed by monitoring cell metabolic activity using a colorimetric assay. RESULTS: We calculated the half maximal inhibitory concentration (IC(50)) at 72 h, which ranged from 0.04 to 0.37 nM for ELQ-300, and from 0.002 to 0.1 nM for ELQ-316 among all cultured parasites tested at 72 h. None of the parasites tested were able to replicate in cultures in the presence of ELQ-300 and ELQ-316 at the maximal inhibitory concentration (IC(100)), which ranged from 1.3 to 5.7 nM for ELQ-300 and from 1.0 to 6.0 nM for ELQ-316 at 72 h. Neither ELQ-300 nor ELQ-316 altered the viability of equine and bovine PBMC at their IC(100) in in vitro testing. CONCLUSIONS: The compounds ELQ-300 and ELQ-316 showed significant inhibitory activity on the main parasites responsible for bovine babesiosis and equine piroplasmosis at doses that are tolerable to host cells. These ELQ drugs may be viable candidates for developing alternative protocols for the treatment of bovine babesiosis and equine piroplasmosis. [Image: see text] BioMed Central 2020-12-03 /pmc/articles/PMC7712603/ /pubmed/33272316 http://dx.doi.org/10.1186/s13071-020-04487-3 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Silva, Marta G. Bastos, Reginaldo G. Stone Doggett, J. Riscoe, Michael K. Pou, Sovitj Winter, Rolf Dodean, Rozalia A. Nilsen, Aaron Suarez, Carlos E. Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi |
title | Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi |
title_full | Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi |
title_fullStr | Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi |
title_full_unstemmed | Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi |
title_short | Endochin-like quinolone-300 and ELQ-316 inhibit Babesia bovis, B. bigemina, B. caballi and Theileria equi |
title_sort | endochin-like quinolone-300 and elq-316 inhibit babesia bovis, b. bigemina, b. caballi and theileria equi |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712603/ https://www.ncbi.nlm.nih.gov/pubmed/33272316 http://dx.doi.org/10.1186/s13071-020-04487-3 |
work_keys_str_mv | AT silvamartag endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT bastosreginaldog endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT stonedoggettj endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT riscoemichaelk endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT pousovitj endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT winterrolf endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT dodeanrozaliaa endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT nilsenaaron endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi AT suarezcarlose endochinlikequinolone300andelq316inhibitbabesiabovisbbigeminabcaballiandtheileriaequi |